Literature DB >> 16941339

Inhibition of multidrug-resistant HIV-1 by interference with cellular S-adenosylmethionine decarboxylase activity.

Birgit Schäfer1, Ilona Hauber, Andrea Bunk, Jochen Heukeshoven, Arne Düsedau, Dorian Bevec, Joachim Hauber.   

Abstract

S-adenosylmethionine decarboxylase (SAMDC), a key enzyme in polyamine biosynthesis, can be specifically inhibited by the experimental drug SAM486A. The pharmaceutical interference with SAMDC activity results in the depletion of the intracellular pool of spermidine and spermine. In particular, low spermidine levels compromise hypusine modification and, thereby, activation of eukaryotic initiation factor 5A (eIF-5A), which is a cellular cofactor of the essential human immunodeficiency virus type 1 (HIV-1) regulatory protein Rev. In the present study, we show that SAM486A efficiently suppresses HIV-1 replication, including the replication of viruses that are resistant to multiple reverse transcriptase and protease inhibitors. At drug concentrations that efficiently inhibit the formation of progeny viruses, no toxic effects of SAM486A on cellular metabolism are observed. It is demonstrated that the antiretroviral effect of SAM486A is based on the fact that Rev activity is severely compromised in drug-treated cells. Thus, inhibition of cellular SAMDC activity may provide a novel strategy to achieve suppression of otherwise drug-resistant viruses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941339     DOI: 10.1086/507043

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

Review 1.  Mammalian polyamine metabolism and function.

Authors:  Anthony E Pegg
Journal:  IUBMB Life       Date:  2009-09       Impact factor: 3.885

2.  Inhibition of HIV Expression and Integration in Macrophages by Methylglyoxal-Bis-Guanylhydrazone.

Authors:  Xia Jin; Michael S McGrath; Hua Xu
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

3.  Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

Authors:  Mainul Hoque; Hartmut M Hanauske-Abel; Paul Palumbo; Deepti Saxena; Darlene D'Alliessi Gandolfi; Myung Hee Park; Tsafi Pe'ery; Michael B Mathews
Journal:  Retrovirology       Date:  2009-10-13       Impact factor: 4.602

4.  Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection.

Authors:  Yegnasew Takele; Tamrat Abebe; Teklu Weldegebreal; Asrat Hailu; Workagegnehu Hailu; Zewdu Hurissa; Jemal Ali; Ermiyas Diro; Yifru Sisay; Tom Cloke; Manuel Modolell; Markus Munder; Fabienne Tacchini-Cottier; Ingrid Müller; Pascale Kropf
Journal:  PLoS Negl Trop Dis       Date:  2013-01-17

5.  Drug-induced reactivation of apoptosis abrogates HIV-1 infection.

Authors:  Hartmut M Hanauske-Abel; Deepti Saxena; Paul E Palumbo; Axel-Rainer Hanauske; Augusto D Luchessi; Tavane D Cambiaghi; Mainul Hoque; Michael Spino; Darlene D'Alliessi Gandolfi; Debra S Heller; Sukhwinder Singh; Myung Hee Park; Bernadette M Cracchiolo; Fernando Tricta; John Connelly; Anthony M Popowicz; Richard A Cone; Bart Holland; Tsafi Pe'ery; Michael B Mathews
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

6.  Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

Authors:  Deepti Saxena; Michael Spino; Fernando Tricta; John Connelly; Bernadette M Cracchiolo; Axel-Rainer Hanauske; Darlene D'Alliessi Gandolfi; Michael B Mathews; Jonathan Karn; Bart Holland; Myung Hee Park; Tsafi Pe'ery; Paul E Palumbo; Hartmut M Hanauske-Abel
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

7.  Abolishing HIV-1 infectivity using a polypurine tract-specific G-quadruplex-forming oligonucleotide.

Authors:  Maike Voges; Carola Schneider; Malte Sinn; Jörg S Hartig; Rudolph Reimer; Joachim Hauber; Karin Moelling
Journal:  BMC Infect Dis       Date:  2016-07-22       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.